TY - JOUR
T1 - Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome
AU - Teede, Helena J.
AU - Misso, Marie L.
AU - Costello, Michael F.
AU - Dokras, Anuja
AU - Laven, Joop
AU - Moran, Lisa
AU - Piltonen, Terhi
AU - Norman, Robert J.
AU - Andersen, Marianne
AU - Azziz, Ricardo
AU - Balen, Adam
AU - Baye, Estifanos
AU - Boyle, Jacqueline
AU - Brennan, Leah
AU - Broekmans, Frank
AU - Dabadghao, Preeti
AU - Devoto, Luigi
AU - Dewailly, Didier
AU - Downes, Linda
AU - Fauser, Bart
AU - Franks, Stephen
AU - Garad, Rhonda M.
AU - Gibson-Helm, Melanie
AU - Harrison, Cheryce
AU - Hart, Roger
AU - Hawkes, Rachel
AU - Hirschberg, Angelica
AU - Hoeger, Kathleen
AU - Hohmann, Femke
AU - Hohmann, Huisartsenpraktijk
AU - Vet, De
AU - Hutchison, Samantha
AU - Joham, Anju
AU - Johnson, Louise
AU - Jordan, Cailin
AU - Kulkarni, Jayashri
AU - Legro, Richard S.
AU - Li, Rong
AU - Lujan, Marla
AU - Malhotra, Jaideep
AU - Mansfield, Darren
AU - Marsh, Kate
AU - McAllister, Veryan
AU - Mocanu, Edgar
AU - Mol, Ben W.
AU - Ng, Ernest
AU - Oberfield, Sharon
AU - Ottey, Sasha
AU - Peña, Alexia
AU - Qiao, Jie
N1 - Funding Information:
The guideline was primarily funded by the Australian National Health and Medical Research Council of Australia (NHMRC) supported by a partnership with the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine. GDG members did not receive payment. Travel expenses were covered by the sponsoring organizations.
Funding Information:
Funding information The guideline was primarily funded by the Australian National Health and Medical Research Council of Australia (NHMRC) supported by a partnership with the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine. GDG members did not receive payment. Travel expenses were covered by the sponsoring organizations. We gratefully acknowledge the contribution of our funding, partner, engaged, and collaborating organizations: The Australian National Health and Medical Research Council (NHMRC) through the funded Centre for Research Excellence in Polycystic Ovary Syndrome (APP1078444) and the members of this Centre who coordinated this international guideline effort. Our partner organizations which co-funded the guideline: American Society for Reproductive Medicine (ASRM) European Society of Human Reproduction and Embryology (ESHRE) Our collaborating and engaged societies and consumer groups: Androgen Excess and Polycystic Ovary Syndrome Society (AEPCOS) American Pediatric Endocrine Society; Asia Pacific Paediatric Endocrine Society (APPES) Asia Pacific Initiative on Reproduction (ASPIRE) Australasian Paediatric Endocrine Group (APEG) Australian Diabetes Society (ADS) British Fertility Society (BFS) Canadian Society of Endocrinology and Metabolism (CSEM) Dietitians Association Australia Endocrine Society (US Endo) Endocrine Society Australia (ESA) European Society of Endocrinology (ESE) European Society for Paediatric Endocrinology (ESPE) Exercise and Sports Science Australia (ESSA) Federation of Obstetric and Gynaecological Societies of India (FOGSI) Fertility Society Australia (FSA) International Society of Endocrinology (ISE) International Federation of Fertility Societies (IFFS) International Federation of Gynecology and Obstetrics (FIGO) Italian Society of Gynaecology and Obstetrics Japanese Society for Paediatric Endocrinology (JSPE) Latin American Society for Paediatric Endocrinology (SLEP); Nordic Federation of Societies of Obstetrics and Gynaecology (NFOG) PCOS Challenge PCOS Society of India Paediatric Endocrine Society (PES) Polycystic Ovary Association Australia (POSSA); Royal Australasian College of Physicians (RACP) Royal Australian College of General Practitioners (RACGP) Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Royal College of Obstetricians and Gynaecologists (RCOG) South African Society of Gynaecology and Obstetrics (SASOG) Verity UK Victorian Assisted Reproductive Technology Association (VARTA) Other relevant organizations are welcome to partner in guideline translation once approved.
Publisher Copyright:
© 2018 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Study Question: What is the recommended assessment and management of women with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference?. Summary Answer: International evidence-based guidelines including 166 recommendations and practice points, addressed prioritized questions to promote consistent, evidence-based care and improve the experience and health outcomes of women with PCOS. What is Known Already: Previous guidelines either lacked rigorous evidence-based processes, did not engage consumer and international multidisciplinary perspectives, or were outdated. Diagnosis of PCOS remains controversial and assessment and management are inconsistent. The needs of women with PCOS are not being adequately met and evidence practice gaps persist. Study Design, Size, Duration: International evidence-based guideline development engaged professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Appraisal of Guidelines for Research and Evaluation (AGREE) II-compliant processes were followed, with extensive evidence synthesis. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength. Participants/Materials, Setting, Methods: Governance included a six continent international advisory and a project board, five guideline development groups (GDGs), and consumer and translation committees. Extensive health professional and consumer engagement informed guideline scope and priorities. Engaged international society-nominated panels included pediatrics, endocrinology, gynecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, public health and other experts, alongside consumers, project management, evidence synthesis, and translation experts. Thirty-seven societies and organizations covering 71 countries engaged in the process. Twenty face-to-face meetings over 15 months addressed 60 prioritized clinical questions involving 40 systematic and 20 narrative reviews. Evidence-based recommendations were developed and approved via consensus voting within the five guideline panels, modified based on international feedback and peer review, with final recommendations approved across all panels. Main Results and the Role of Chance: The evidence in the assessment and management of PCOS is generally of low to moderate quality. The guideline provides 31 evidence based recommendations, 59 clinical consensus recommendations and 76 clinical practice points all related to assessment and management of PCOS. Key changes in this guideline include: (a) considerable refinement of individual diagnostic criteria with a focus on improving accuracy of diagnosis; (b) reducing unnecessary testing; (c) increasing focus on education, lifestyle modification, emotional wellbeing and quality of life; and (d) emphasizing evidence based medical therapy and cheaper and safer fertility management. Limitations, Reasons for Caution: Overall evidence is generally low to moderate quality, requiring significantly greater research in this neglected, yet common condition, especially around refining specific diagnostic features in PCOS. Regional health system variation is acknowledged and a process for guideline and translation resource adaptation is provided. Wider Implications of the Findings: The international guideline for the assessment and management of PCOS provides clinicians with clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports the guideline with an integrated evaluation program.
AB - Study Question: What is the recommended assessment and management of women with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference?. Summary Answer: International evidence-based guidelines including 166 recommendations and practice points, addressed prioritized questions to promote consistent, evidence-based care and improve the experience and health outcomes of women with PCOS. What is Known Already: Previous guidelines either lacked rigorous evidence-based processes, did not engage consumer and international multidisciplinary perspectives, or were outdated. Diagnosis of PCOS remains controversial and assessment and management are inconsistent. The needs of women with PCOS are not being adequately met and evidence practice gaps persist. Study Design, Size, Duration: International evidence-based guideline development engaged professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Appraisal of Guidelines for Research and Evaluation (AGREE) II-compliant processes were followed, with extensive evidence synthesis. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength. Participants/Materials, Setting, Methods: Governance included a six continent international advisory and a project board, five guideline development groups (GDGs), and consumer and translation committees. Extensive health professional and consumer engagement informed guideline scope and priorities. Engaged international society-nominated panels included pediatrics, endocrinology, gynecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, public health and other experts, alongside consumers, project management, evidence synthesis, and translation experts. Thirty-seven societies and organizations covering 71 countries engaged in the process. Twenty face-to-face meetings over 15 months addressed 60 prioritized clinical questions involving 40 systematic and 20 narrative reviews. Evidence-based recommendations were developed and approved via consensus voting within the five guideline panels, modified based on international feedback and peer review, with final recommendations approved across all panels. Main Results and the Role of Chance: The evidence in the assessment and management of PCOS is generally of low to moderate quality. The guideline provides 31 evidence based recommendations, 59 clinical consensus recommendations and 76 clinical practice points all related to assessment and management of PCOS. Key changes in this guideline include: (a) considerable refinement of individual diagnostic criteria with a focus on improving accuracy of diagnosis; (b) reducing unnecessary testing; (c) increasing focus on education, lifestyle modification, emotional wellbeing and quality of life; and (d) emphasizing evidence based medical therapy and cheaper and safer fertility management. Limitations, Reasons for Caution: Overall evidence is generally low to moderate quality, requiring significantly greater research in this neglected, yet common condition, especially around refining specific diagnostic features in PCOS. Regional health system variation is acknowledged and a process for guideline and translation resource adaptation is provided. Wider Implications of the Findings: The international guideline for the assessment and management of PCOS provides clinicians with clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports the guideline with an integrated evaluation program.
KW - assessment
KW - evidence-based
KW - GRADE
KW - guideline
KW - management
KW - polycystic ovary syndrome
UR - http://www.scopus.com/inward/record.url?scp=85050494365&partnerID=8YFLogxK
U2 - 10.1111/cen.13795
DO - 10.1111/cen.13795
M3 - Article
AN - SCOPUS:85050494365
SN - 0300-0664
VL - 89
SP - 251
EP - 268
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 3
ER -